Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
136
resultados
Última actualización
11/09/2026 [07:00:00]
Resultados 25 a 50 de 136
Resumen de: WO2026177370A1
A method for adjusting insulin comprises the steps of: an analysis apparatus acquiring carbohydrate intake data, continuous blood glucose data, and insulin administration data; the analysis apparatus determining a meal time point on the basis of the continuous blood glucose data; the analysis apparatus setting, as a pre-meal blood glucose value, a minimum blood glucose value during a preset period before the meal time point; and the analysis apparatus determining, on the basis of the pre-meal blood glucose value, the amount of insulin to be injected.
Resumen de: US20260253354A1
A system and method for interactive three-dimensional visualization of physiological stress effects on the human body uses biomarker correlation algorithms to determine physiological responses to physical trauma and toxic stress events. The system receives stress event data, calculates biomarker levels including cortisol, blood pressure, blood sugar, and inflammatory markers, and identifies affected organ systems including cardiovascular, nervous, endocrine, digestive, immune, and reproductive systems. Three-dimensional anatomical models are modified with visual characteristics depicting stress-induced changes based on the biomarker data, including color alterations, geometric deformations, and animated effects. A temporal progression interface enables visualization of immediate, short-term, and long-term physiological effects. Spatial audio synchronized with visual animations provides immersive auditory feedback. Cross-platform rendering modules optimize visualization for mobile devices, desktop computers, tablets, virtual reality headsets, and augmented reality glasses. The system provides for real-time interactive manipulation of anatomical visualizations, particularly for pediatric toxic stress education related to corporal punishment.
Resumen de: US20260248422A1
A personal electronic device and wearable sensing system includes one or more dermal-contact electrochemical sensors integrated into one or more skin-contact surfaces of the electronic device, wearable, accessory, or interactive electronic system. The electrochemical sensors obtain measurements indicative of one or more analyte classes associated with a user. One or more additional sensors obtain non-electrochemical measurements associated with the user. A sensor-fusion module derives electrochemical and non-electrochemical features and generates a unified state estimate. One or more inference modules determine a user-state output based on the unified state estimate and a comparison of electrochemical-derived information, or features derived therefrom, to an individualized baseline reference profile associated with the user. In some embodiments, the analyte classes include endogenous physiological markers including glucose-related markers, exogenous exposure analytes, or both. In some embodiments, a credential derived from the individualized baseline reference profile is portable across multiple authorized devices within a trusted ecosystem.
Resumen de: US20260248419A1
Provided is a blood glucose data management method including identifying first blood glucose data based on a blood glucose sensor, identifying a verification dataset corresponding to the first blood glucose data, estimating whether at least a portion of the blood glucose sensor is detached from a user's body based on a comparison between a pattern corresponding to the verification dataset and a reference pattern, and suspending output of the first blood glucose data if detachment is estimated.
Resumen de: EP4797275A1
A medication delivery system, including a wearable device configured to automatically deliver medication based on food order information received from a user computing device. The medication is delivered via a pump, and the medication may be insulin. The food order information includes timing information and/or information about the food ordered necessary to change a medication delivery. A controller determines a medication adjustment based on an estimated physiological response to the food order information. A delivery pump automatically delivers the medication, e.g., an insulin bolus, prior to or in anticipation of food consumption.
Resumen de: GR1011264B
The present invention consists in an assisted driving system for drivers with diabetes, installable into vehicles that have a central brain (16), a steering system (EPS - Electric Power Steering) (10), a braking system (EHB - Electrohydraulic Brakes) (11) and a telematics unit (15). It consists of: a) a biometric identification unit (FacelD) (2), b) a camera for monitoring the physical state of the driver (Driver Monitoring System) (7), c) a Lidar sensor (9), d) a Radar sensor (9,17), e) a GPS receiver (14), f) a continuous glucose monitoring sensor (CGM sensor) (4), g) a high-performance microcontroller (3) and h) a CAN-bus interface adapter to connect the high-performance microcontroller to the central brain. By the implemented assisted driving method, the system, upon detecting that the glucose level falls below 80 mg/dL, takes control of the vehicle, steering it safely to a location where it can be immobilized safely.
Resumen de: ZA202508070B
Provided are anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments, and the uses thereof.
Resumen de: EP4796034A2
0001 The present disclosure relates to a body-attachable unit for continuously measuring blood glucose. As the body-attachable unit is manufactured to be assembled in an applicator, additional effort is minimized such that the body-attachable unit can be attached to the body by simply operating the applicator. In particular, since the body-attachable unit is provided with a wireless communication chip such that communication with an external terminal is possible, the body-attachable unit can be used simply and conveniently without additional work of connecting a separate transmitter, and thus can be maintained more easily. In addition, since the body-attachable unit is operated by an operation of a user after being attached to the body, the start time of the operation can be adjusted to an appropriate time according to the needs of the user. Accordingly, the body-attachable unit can be operated in a stabilized state, thereby allowing for more accurate blood glucose measurement.
Resumen de: EP4796158A1
0001 L'invention concerne un ensemble (1) d'administration d'un médicament liquide, de préférence de l'insuline, comprenant une pompe (10) de perfusion comprenant un réservoir (11) pour stocker le médicament liquide, et un premier connecteur (13) comprenant un taraudage (14), en communication fluidique avec le réservoir (11), et un cathéter (20) comprenant un tuyau flexible (21) équipé d'un second connecteur (23) comprenant un filetage (24) complémentaire du taraudage (14) du premier connecteur (13) de manière à pouvoir coupler par vissage les premier et second connecteurs (13, 23), l'un à l'autre, et ainsi raccorder fluidiquement le cathéter (20) à la pompe (10). Le couplage par vissage des premier et second connecteurs (13, 23), l'un à l'autre, comprend un déplacement en rotation (R) relatif de l'un par rapport à l'autre, selon un angle de rotation compris entre 100° et 200°.
Resumen de: EP4796031A2
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.
Resumen de: EP4796143A2
0001 Disclosed are systems, devices, methods and computer-readable medium products that implement a vibrational event by a wearable drug delivery device. The wearable drug delivery device includes vibrational actuators that vibrate in response to a control signal from a controller. The controller may be controlled by an external device that issues command signals with instructions related to settings of the vibrational event. The vibrational event settings may be modified based on signals received from sensors on the wearable drug delivery device. The vibrational events may be implemented as an element of a site maintenance plan that alleviates the degeneration of tissue at one or more body attachment sites of the wearable drug delivery device.
Resumen de: US20260242737A1
0000 A culture medium and a culture medium additive which can promote myogenic differentiation. The culture medium and a culture medium additive contain ergothioneine, ascorbic acid 2-glucoside, ascorbic acid, or a combination thereof. A kit, pharmaceutical composition, food, and drink may also promote myogenic differentiation.
Resumen de: US20260241096A1
0000 An infusion element for infusing a substance into a body of a person, comprising: a housing that is suitable for being attached to the skin of said person; an infusion means for infusing the substance into the body of said person, said infusion means being arranged on and/or protruding from the first surface of the housing; at least one sensor for sensing a characteristic of the person, said sensor being arranged on and/or protruding from the first surface of the housing; wherein in use of the infusion element the infusion means is arranged for infusing said substance at a first depth and said sensor is arranged for sensing the characteristic at a second, different depth. A system for regulating the concentration of glucose in the blood of a person comprising such an infusion element.
Resumen de: US20260240464A1
0000 A composition for blood glucose measurement includes a copolymer including three types of monomers having a hydrophobic group, a hydrophilic group, and a boronic acid moiety, and a conductive material mixed with the copolymer, thereby enabling volume changes in response to glucose to be converted into electrical signals. An electrochemical sensor for blood glucose measurement includes a working electrode that includes the composition.
Resumen de: US20260240459A1
0000 This invention relates to a low-cost portable multispectral detection method and device for early disease diagnosis. The device is based on a CMOS multispectral sensor chip and uses natural light or halogen lamps as the light source to non-invasively detect physiological parameters from the eyes, oral cavity, and/or skin of patients. The device captures reflected light data of different wavelengths using the multispectral chip and processes the data to generate image information, subsequently identifying the corresponding test areas. By processing the initial spectral information, the device provides accurate spectral data analysis to determine physiological parameters such as glucose etc., enabling early diagnosis of diseases such as diabetes, etc. It features real-time data analysis and wireless data transmission, offering a convenient solution for large-scale health monitoring and telemedicine.
Resumen de: WO2026171056A1
Disclosed in the present application are a blood glucose assessment method, a user interface, and a related apparatus. The method involves two phases: a calibration phase and an assessment phase. In the calibration phase, physical sign data used for reflecting a physical condition of a user, and a blood glucose value can be acquired, and a personalized blood glucose assessment model applicable to the user is obtained on the basis of the physical sign data and the blood glucose value. Then, in the assessment phase, physical sign data of the user is acquired, and a blood glucose result of the user is assessed on the basis of the physical sign data and the blood glucose assessment model, wherein the blood glucose result can be used for indicating a blood glucose condition of the user. In the method, in the calibration phase, the model is determined on the basis of the physical sign data and the blood glucose value, which improves the accuracy of the model. Moreover, in the assessment phase, the blood glucose condition of the user can be assessed without acquiring the blood glucose value, so that the trouble of acquiring the blood glucose value is reduced, and the blood glucose result that is accurate and conforms to an actual condition of the user can be obtained.
Resumen de: US20260241095A1
0000 An infusion system comprising: a device configured to deliver medication to a user through an infusion catheter, wherein the device includes a housing configured to receive the infusion catheter and to maintain the infusion catheter in the user after insertion; and a detachable activation mechanism for deploying the device for delivering medication to the user, wherein the detachable activation mechanism comprises a trigger and a retraction mechanism that includes an introducer needle for introducing the infusion catheter into the user, wherein the detachable activation mechanism is configured to releasably connect to the housing, wherein the detachable activation mechanism is configured to insert the infusion catheter into the user, automatically release the detachable activation mechanism from the housing responsive to activation of the trigger and automatically retract the introducer needle into the needle retraction assembly to shield the needle upon the automatic release of the detachable activation mechanism.
Resumen de: US20260240457A1
Provided is a sensor applicator assembly for a blood glucose monitoring including a body-attachable unit including an upper frame and a lower frame that is disposed under the upper frame and has a surface attached to a body and an applicator within which the body-attachable unit is disposed. The upper frame includes a first area and a second area disposed under the first area and in contact with the lower frame. A perimeter of an outer peripheral surface of the second area is identical to a perimeter of an outer peripheral surface of the lower frame.
Resumen de: US20260241109A1
0000 Systems, methods, and devices relate, generally, to autonomous dose injection. One or more examples relate to a durable insulin injection device. Such a durable dose injection device may include a chamber, a drive mechanism, a logic circuit, and an actuator. The chamber may be to receive a prefilled insulin cartridge. The drive mechanism may be to apply force to a plunger of a received prefilled insulin cartridge, the plunger arranged to move within the received cartridge responsive to force applied by the drive mechanism and thereby push fluid in the received cartridge toward an interface for dispensing fluid. The logic circuit may be to receive analyte data for the user and calculate a target amount of insulin to deliver to a user. The dose-ready confirmation actuator may be for the user to actuate to cause the delivery of insulin to the user. In one or more examples, the durable insulin injection device does not provide the user with an indication of the calculated target amount of insulin for non-zero calculated target amounts of insulin.
Resumen de: US20260240467A1
0000 A method for compensating for a life-lengthening agent for a glucose sensor includes accessing first and second electrochemical impedance spectroscopy (EIS) values of at least one parameter based on first and second EIS procedures performed on EIS signals from a working electrode of the glucose sensor, calculating a change in the at least one parameter between the first and second EIS values, estimating a concentration of the agent based on the change in the at least one parameter, and calculating a model effect in response to the concentration. In a case where the model effect is not greater than the threshold, the method further includes adjusting a sensor glucose value based on the concentration and sensor signals from the working electrode, and displaying the adjusted sensor glucose value.
Resumen de: US20260241102A1
0000 Disclosed herein are techniques related to automatic real-time meal detection. In some embodiments, the techniques involve obtaining a plurality of glucose concentration values and a plurality of plasma insulin concentration values. At least one of the plurality of glucose concentration values is obtained within a time range of a determination of a respective plasma insulin concentration value of the plurality of plasma insulin concentration values. The techniques further involve generating an output based on applying a meal detection model to the plurality of glucose concentration values and the plurality of plasma insulin concentration values and determining, based on the output, that a glucose concentration value of the plurality of glucose concentration values corresponds to an ongoing glycemic response to a meal.
Resumen de: EP4793962A1
0001 The invention discloses a method of locating a lost device in a diabetes management system, the diabetes management system comprises at least one wearable medical device; at least one personal management device and a secondary management device, at least one of the personal management device and the secondary management device is configured to control the wearable medical device, the personal management device and the secondary management device are communicative connection with each other; when either the personal management device or the secondary management device is determined as lost, the other device is used to locate the lost one, thereby enabling the user to retrieve it with ease.
Resumen de: KR20200036122A
The present invention relates to a body attachment unit for continuous blood glucose measurement. According to the present invention, a body attachment unit is manufactured in an assembled state in an applicator to minimize extra additional work so that the body attached unit can be attached to a body only by simply operating the applicator. In particular, the body attached unit can be simply and easily used without additional work of connecting an extra transmitter by having a wireless communication chip to communicate with an external terminal. Maintenance of the body attached unit can also be more easily performed. In addition, the body attached unit can be operated by the operation of a user once the body attached unit is attached to the body of the user, and an operation start time point can be adjusted to an appropriate time point as needed. Therefore, the body attached unit can be operated in a more stabilized state to measure blood glucose more accurately.
Resumen de: US20260232892A1
A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying insulin and glucagon; at least two infusion sets; at least one sensor for measuring a glucose concentration in the blood of said person; and a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.
Nº publicación: US20260232901A1 13/08/2026
Solicitante:
INREDA DIABETIC B V [NL]
INREDA DIABETIC B.V.
Resumen de: US20260232901A1
A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying at least one and preferably two substances to said person; at least one and preferably two infusion sets connectable to said device; at least one sensor for measuring a glucose concentration in the blood of said person; a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
BOPI
Sede Electrónica
